nalysis of Serum Concentration of CYFRA21-1 in Chronic Kidney Disease Patients_West China Medical Journal

Authors：

Department of Nephrology, the Third People′s Hospital of Chengdu, Chengdu, Sichuan 610031, P.R.China;

Corresponding author：

Keywords：

慢性肾脏病; 细胞角蛋白19; CYFRA21-1

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

【摘要】目的 探讨细胞角蛋白19的可溶性片段CYFRA21-1在慢性肾脏病（chronic kidney disease，CKD）患者血清中的表达及其临床意义。方法 2008年10月-2009年4月随机选取45例CKD患者，根据肌酐清除率（creatinine clearance rate，Ccr）的大小分为Ccr lt;15 mL/min组（23例）和Ccr gt;15 mL/min组（22例），并以正常体检者（10例）为正常对照组，肺鳞癌患者（10例）为阳性对照组，每位参与研究者取血后采用酶联免疫吸附法测定血清CYFRA21-1的浓度。结果正常对照组、阳性对照组、Ccr gt;15 mL/min组和Ccr lt;15 mL/min组的血清CFRA21-1浓度分别为（1.720±0.535）、（21.010±11.809）、（3.310±1.569）和（5.090±1.306） ng/mL。与正常对照组比较，其余3组的CYFRA21-1浓度均显著升高，有统计学意义（P lt;0.05），且均值大于正常参考值（0~3.3 ng/mL）；Ccr gt;15 mL/min组和Ccr lt;15 mL/min组的CFRA21-1浓度显著低于阳性对照组，有统计学意义（P lt;0.05）；两个实验组间随着Ccr的降低，CYFRA21-1浓度升高，有统计学意义（P lt;0.05）。结论 CKD患者血清CYFRA21-1水平的升高与肾功能减退存在一定关系，可将其作为临床上预测肾脏纤维化程度的指标。
【Abstract】 Objective To discuss the clinical Between significance of cytokeratin 19 fragment (CYFRA21-1) in patients with chronic kidney disease (CKD). Methods From October 2008 to April 2009, 45 inpatients were randomly selected and assigned into three groups according to creatinine clearance rate (Ccr) level: Ccr lt;15 mL/min, Ccr gt;15 mL/min. Ten healthy volunteers were chosen as control group, and other 10 patients with lung squamous cell carcinoma as positive control group. ELISA was used to measure the serum concentration of CYFRA21-1. Results Compared with control group, the serum concentration of CYFRA21-1 in CKD groups and positive control group was elevated (P lt;0.05). As the Ccr decreased, the serum concentration of CYFRA21-1 was elevated (P lt;0.05) in two CKD groups. Conclusion Serum concentration of CYFRA21-1 in CKD patients has a relationship with the renal function decrease, and may be used as an indication of renal interstitial fibrosis (RIF).

Citation： CHENG Gong,CHEN Zejun,QUAN Dayong,WANG Ping. nalysis of Serum Concentration of CYFRA21-1 in Chronic Kidney Disease Patients. West China Medical Journal, 2010, 25(9): 1607-1608. doi: Copy

1.	Mizuguchi S, Nishiyama N, Iwata T, et al. Clinical value of serum cytokeratin 19 fragment and sialyl-Lewis x in non-small cell lung cancer[J]. Ann Thorac Surg, 2007, 83(1): 216-221.
2.	Xiaofang Y, Yue Z, Xialian X, et al. Serum tumour markers in patients with chronic kidney disease[J]. Scand J Clin Lab Invest, 2007, 67(6): 661-667.
3.	National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification[J]. Am J Kidney Dis, 2002, 39(2 Suppl 1): S1-S266. Comment in: Am J Kidney Dis, 2008, 51(2): 346.
4.	Sun SS, Hsieh JF, Tsai SC, et al. Cytokeratin fragment 19 and squamous cell carcinoma antigen for early prediction of recurrence of squamous cell lung carcinoma[J]. Am J Clin Oncol, 2000, 23(3): 241-243.
5.	Kashiwabara K, Kishi K, Nakamura H, et al. Mechanism of increased serum cytokeratin 19 fragment levels in patients with diabetic nephropathy as a model of chronic renal failure[J]. Intern Med, 1998, 37(11): 917-921.
6.	Takeuchi S, Saitoh H, Yoshida K, et al. The clinical usefulness of urinary determinations of cytokeratin 19 fragment (CYFRA 21-1) in urothelial tumor[J]. Hinyokika Kiyo, 1995, 41(8): 589-592.
7.	Romero S, Fernández C, Arriero JM, et al. CEA, CA15-3 and CYFRA21-1 in serum and pleural fluid of patients with pleural effusions[J]. Eur Respir J, 1996, 9(1): 17-23.
8.	Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis[J]. Am J Pathol, 2001, 159(4): 1465-1475.

1. Mizuguchi S, Nishiyama N, Iwata T, et al. Clinical value of serum cytokeratin 19 fragment and sialyl-Lewis x in non-small cell lung cancer[J]. Ann Thorac Surg, 2007, 83(1): 216-221.
2. Xiaofang Y, Yue Z, Xialian X, et al. Serum tumour markers in patients with chronic kidney disease[J]. Scand J Clin Lab Invest, 2007, 67(6): 661-667.
3. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification[J]. Am J Kidney Dis, 2002, 39(2 Suppl 1): S1-S266. Comment in: Am J Kidney Dis, 2008, 51(2): 346.
4. Sun SS, Hsieh JF, Tsai SC, et al. Cytokeratin fragment 19 and squamous cell carcinoma antigen for early prediction of recurrence of squamous cell lung carcinoma[J]. Am J Clin Oncol, 2000, 23(3): 241-243.
5. Kashiwabara K, Kishi K, Nakamura H, et al. Mechanism of increased serum cytokeratin 19 fragment levels in patients with diabetic nephropathy as a model of chronic renal failure[J]. Intern Med, 1998, 37(11): 917-921.
6. Takeuchi S, Saitoh H, Yoshida K, et al. The clinical usefulness of urinary determinations of cytokeratin 19 fragment (CYFRA 21-1) in urothelial tumor[J]. Hinyokika Kiyo, 1995, 41(8): 589-592.
7. Romero S, Fernández C, Arriero JM, et al. CEA, CA15-3 and CYFRA21-1 in serum and pleural fluid of patients with pleural effusions[J]. Eur Respir J, 1996, 9(1): 17-23.
8. Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis[J]. Am J Pathol, 2001, 159(4): 1465-1475.

West China Medical Journal

nalysis of Serum Concentration of CYFRA21-1 in Chronic Kidney Disease Patients

Abstract Full text Figures/Tables Video References Cited by

Format

Content